Holen Sie sich die Stockscreener-App
15.06
0.60%
0.09
Handel nachbörslich:
15.06
Schlusskurs vom Vortag:
$14.97
Offen:
$15.09
24-Stunden-Volumen:
1.78M
Relative Volume:
0.85
Marktkapitalisierung:
$47.39B
Einnahmen:
$30.08B
Nettoeinkommen (Verlust:
$710.16M
KGV:
69.02
EPS:
0.2182
Netto-Cashflow:
$4.45B
1W Leistung:
+1.07%
1M Leistung:
+3.36%
6M Leistung:
+14.61%
1J Leistung:
+16.56%
1-Tages-Spanne:
$15.04
$15.13
1-Wochen-Bereich:
$14.56
$15.13
52-Wochen-Spanne:
$12.80
$15.43
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Vergleichen Sie TAK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
RGC
Regencell Bioscience Holdings Ltd
|
20.19 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.79 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.42 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.56 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com
MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com
Takeda files executive compensation report with SEC - Investing.com
Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl
Stocks With Rising Relative Strength: Novartis ADR - inkl
Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus - Wiley Online Library
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
Takeda continues stock plan for management in 2025 - Investing.com
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? - Yahoo Finance
A significant driver of top-line growth: Takeda Pharmaceutical Co ADR (TAK) - Sete News
Nothing is Better Than C.H. Robinson Worldwide, Inc (CHRW) stock at the moment - Sete News
Takeda Pharmaceutical Co ADR Inc. (TAK) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Carmax Inc: Analyzing KMX Stock Trends - investchronicle.com
Klaviyo Inc (KVYO) Stock: The Story of a 52-Week Stock Range - investchronicle.com
You might want to take a look at Denison Mines Corp (DNN) now - Sete News
A Look at Cousins Properties Inc (CUZ) Shares in the Recent Past Indicates Growth - Sete News
A better buy-in window may exist right now for Cheesecake Factory Inc (CAKE) - Sete News
Stocks of CN Energy Group Inc (CNEY) are poised to climb above their peers - Sete News
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - knoxdaily.com
Cintas Corporation [CTAS] Insider Activity: An Update for Investors - knoxdaily.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance
Organon expands board with new director from Takeda - Investing.com
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN
Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize
Morgan Stanley lifts Takeda stock rating, raises target to JPY5,500 - Investing.com
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo
PD Stock on the Rise: A Promising Investment - The InvestChronicle
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):